Microsaic Systems Wins R&D 100 Award for the World’s Most Compact Mass Spectrometer

(Woking, June 21st 2012) - Microsaic Systems plc, the high technology company developing next generation mass spectrometry instruments, is proud to announce that its 3500 MiD mass spectrometer has been chosen as an R&D 100 award winner by an independent judging panel and the editors of R&D Magazine. The award recognises the 3500 MiD as one of the most technologically significant products to enter the marketplace in 2011. Microsaic is the first and only company to have commercialised MS (mass spectrometry) technology on a chip. The instrument distinguished itself among other entries as the chips allow production of MS detectors that are smaller, lighter, consume less energy, are easier to maintain and cheaper to run than conventional MS systems. 

MS is widely accepted as one of the most reliable methods for identifying chemicals, and MS systems are used to accurately identify the chemicals that make up gaseous, liquid and solid samples.  MS is used across a range of sectors including government, energy, utilities, pharmaceuticals, environmental, food & drink, healthcare and industrial chemicals.  Although fast and sensitive, typical MS systems are large, heavy, energy intensive, expensive and complex to use, as a result, MS systems tend to be shared, central facilities. The 3500 MiD represents a step change in the ease of use and footprint of mass spectrometry.

Most revolutionary is the fact that the 3500 MiD, uniquely, is fully self contained, making it highly portable. All other commercial mass spectrometers have external vacuum pumps, which typically sit on the floor and connect to the instrument with vacuum hoses. The 3500 MiD’s small size – about one third that of the main unit of typical competitors - means it can be easily incorporated within a stack or cluster of instruments on a particular chemist’s work space – it is even small enough to sit inside a fume hood. This results in greater workplace productivity, by giving chemists access to immediate results, offering economic benefit in areas such as drug discovery and synthesis. It will also bring the accuracy and reliability of mass spectrometry to on-site analysis applications such as sports forensics, food & beverage quality, and oil and gas exploration.

“The awards have long been a benchmark of excellence so we are delighted to have been selected for the R&D 100 award - the competition has been strong this year so it is a great achievement to be acknowledged by industry leaders as one of the most valuable and significant products released to the market,” said Professor Eric Yeatman, CEO of Microsaic Systems. “The 3500 MiD is the culmination of over a decade of research, bringing together two high tech fields – chemical analysis and silicon micro-engineering – to make possible a transformative capability in detection. Its low operating cost and small footprint make the 3500 MiD deployable in a wide range of applications where mass spectrometry has not been able to reach until now – a true innovation.”

For more information about the Microsaic 3500 MiD system, please call +44 1483 751 577, email media@microsaic.com or visit www.microsaic.com

About Microsaic Systems plc

Microsaic Systems plc is a high technology company developing and marketing next generation mass spectrometry (MS) instruments for the analysis of gaseous, liquid and solid samples. Microsaic has successfully miniaturised mass spectrometry by integrating the key MS components onto patented chip technologies called ionchip®, spraychip® and vac-chip. Microsaic’s MS products retain the speed and sensitivity of larger, conventional MS systems but are substantially smaller, lighter, consume less energy and have lower running costs. The Company’s first product, the Microsaic 3500 MiD®, was launched in January 2011 and is the world’s smallest MS system.

Microsaic Systems plc was established in 2001 to develop miniaturized MS instruments based on Micro-Electrical-Mechanical Systems (MEMS) originating at the highly regarded Optical and Semiconductor Devices Group at Imperial College London. Microsaic has subsequently established a large portfolio of 88 patents, of which 36 are granted. The Company has been based at headquarters in Woking, UK since September 2004 and was admitted to AIM, a market of the London Stock Exchange, in April 2011 (ticker: MSYS).

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA, United Kingdom Tel: + 44 1477 539539  Fax: +44  1477 539540  mail to: pr@scottpr.com

Greenphire Selected as a PACT Enterprise Award Finalist

King of Prussia, PA, 08 February, 2012 – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that it has been chosen as one of three finalists for the Philadelphia Alliance for Capital and Technologies (PACT) Enterprise Award in the Technology Startup division. Selection for the award was based on Greenphire’s established success in delivering an innovative product to meet a significant market need, potential for significant growth, managerial ability and record of achieving success, and demonstration of success via significant business milestones such as raising capital and achieving revenue growth.

Greenphire and the other Enterprise Award finalist companies will be honored at the 19th Annual Enterprise Awards gala of 1,200 prominent business leaders on Thursday, May 3, 2012, at the Hilton Philadelphia City Line.

The Enterprise Award finalists were selected from among hundreds of Greater Philadelphia area technology and life sciences companies nominated by entrepreneurs, investors, bankers, journalists, and industry insiders. Past winners include Siemens Healthcare, BioClinica, Shire Pharmaceuticals, and other leaders in the pharmaceutical and clinical trials industry. The PACT board of independent judges conducted a rigorous two-month selection process to determine the finalists, and will continue to evaluate each finalist’s ongoing performance in order to choose the winners.

“This year the number of applicants and, more importantly, the quality of applicants was at an all-time high,” said Charles Robins, managing director at Fairmount Partners and lead judge for the Enterprise Awards. “We have been through an era where companies have had to live on less capital, and what’s happened is we have a new generation of companies and of entrepreneurs who are growing successfully. It sets a very optimistic base for our future, and all of the judges this year felt that all of the companies being honored as finalists are superb choices.”

Greenphire CEO Sam Whitaker expressed the company’s enthusiasm with the selection, saying “The Enterprise Award is the top regional recognition in our industry and we are thrilled to be considered for this prestigious honor. Greenphire has seen rapid expansion over the past year and this selection comes at the perfect time for us to continue establishing ourselves as the leaders in clinical payments both here in the greater Philadelphia region and across the clinical trials industry.”

A full list of this year’s Enterprise Award finalists and past winners can be found on the PACT website at http://pact.gpcc.com/

About Greenphire

Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.

For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.

Analytical Technology Expands Team to Increase Capacity as Prestigious Contract Wins are Secured

Manchester, UK (January, 9, 2012) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that the company is expanding its team to accommodate increasing business as it continues to grow as the leading supplier of water monitoring instrumentation to the UK’s utility industry. Analytical Technology has expanded its workforce by more than 20%, including hiring two new employees to strengthen its Customer Service offering and meet the demands of new framework agreements with companies including Wessex Water and Yorkshire Water.

Following a series of high profile contract wins, Analytical Technology is determined to maintain the same high standards of customer support to complement its leading instrumentation. Lisa Briggs joins Analytical Technology as service administrator and is responsible for organising the top quality customer service and training that the company delivers to its customers. Lisa will coordinate the activities of Analytical Technology’s team of service engineers, ensuring that they are available to respond to challenges, such as disinfection issues, that can occur at wastewater treatment plants and need immediate attention. Lisa has a background in customer service and operational management, working at companies including AVIVA and Apropos Tectonic Ltd, ensuring that projects were delivered on time and in accordance with customer requirements.

Analytical Technology’s customer service team has also been bolstered with the appointment of Ann Jones as financial administrator. Both new employees will ensure that Analytical Technology’s customers receive a seamless and efficient service.

Analytical Technology is a UK and European specialist electrochemical sensor manufacturer, providing a range of toxic gas detectors and water monitors including peracetic acid, hydrogen peroxide, residual sulphite and chlorine. The company was set up in 1998 and from then on has enjoyed increasing success. Recent contract wins with Wessex Water, Severn Trent Water, Thames Water and Yorkshire Water mean that Analytical Technology now supplies water monitoring instrumentation to 7 out of the 10 major utility companies in the UK. In addition to this, Analytical Technology provides gas and water monitors to many food and beverage, industrial and pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Coca Cola and Britvic.

The growing success of Analytical Technology can largely be attributed to the high standard of customer service delivered by the company. Analytical Technology provides specialist product-specific customer training at its head quarters in Saddleworth, Manchester. Maintenance services and in-depth training workshops provided at customers’ premises are also part of the company’s comprehensive after-sales support.

Dr. Michael Strahand, General Manager Europe at Analytical Technology, comments: “Our decision to expand the Analytical Technology team reinforces our commitment to providing top quality customer service and I am delighted to welcome our new employees to their roles. Analytical Technology has gone from strength to strength since its inception in 1998 and we are proud to list many leading brands and companies in the food and beverage, cosmetic, utility and pharmaceutical sectors as our customers. Top class customer service is essential in this industry, where rapid response times to situations such as water treatment issues are essential to maintaining a safe and continuous water supply in water treatment and manufacturing plants.”

For more information on Analytical Technology’s water and gas monitoring instrumentation, please call or +44(0)800 8046 062, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.

-ENDS-

For further press information please contact: Lindsay Baldry, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: ati@scottpr.com

Synergy Health Announces Contract Extension With Homerton University Hospital

Swindon, UK (11 November 2011) – Synergy Health plc, the leading provider of specialist outsourced services to healthcare providers, is pleased to announce that Homerton University Hospital NHS Foundation Trust has extended its contract with the company, entering into a new sterile services agreement (for decontamination of surgical instruments) which also includes the supply of over 10,000 theatre consumables (single use bowl sets). Synergy Health delivers a range of specialist outsourced services to healthcare providers across Europe and China, aimed at supporting customers to improve the quality and efficiency of their activities, reducing risks to patients and clients. The contract is a continuation of the long standing relationship between the organizations.

The contract was awarded following a competitive tender process, with Synergy Health offering a number of innovative solutions. The company’s CEO, UK and Ireland, Adrian Coward said: “Synergy Health is a trusted and proven partner to the NHS, continually striving for mutual success based on trust, innovation and accountability. It is deeply committed to delivering the highest quality in everything it does, going the extra mile to make a difference; solve problems and reduce risk. For Homerton we incorporated single use and reusable theatre consumables into the agreement, offering significant price benefits and added value, with the potential of increasing our supply of medical products.”

Synergy Health has been running the Trust’s sterile services department for a number of years, processing around 1 million items per year. The company is fully engaged with economic pressures facing the NHS and its services offer significant economies of scale and efficiency savings to clients, backed by an exemplary track record in regulatory compliance. The company believes that improved business outcomes can be achieved by working collaboratively.

Synergy Health works with leading instrument suppliers on improving design and reducing tray defects and enjoys very low defect rates. A testament to the established relationship between Synergy Health and its customers are the high quality standards hospitals are continuing to experience, benefiting from exceptionally low defect and rejection rates from both sides of the partnership.

Adrian Coward continued: “This continued collaboration demonstrates the success of long-lasting relationships and confirms that public and private sectors can work together to provide excellent integrated services to patients. The innovative solutions offer value for money, quality enhancements and improved services, from both in-house suppliers and third party distributors.”

To learn more Synergy Health’s services, please visit www.synergyhealthplc.com, contact decontamination@synergyhealthplc.com or alternatively call 01582 501234

Notes to editors:

About Synergy Health

Synergy Health is the largest provider of outsourced hospital sterilisation services in Europe with 19 facilities across the UK and further facilities in Belgium, Netherlands and China. It safely sterilises around 60 million surgical instruments each year from NHS acute and primary Trusts and the independent sector throughout the country.

Synergy’s services offer significant economies of scale and efficiency savings to the NHS, is fully engaged with the reforms in healthcare and is committed to supporting the NHS in reducing its cost burden while striving for the highest quality of care and best outcomes for patients.

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: synergy@scottpr.com

EXCO INTOUCH SECURES GROWTH INVESTMENT FROM SEP

Mobile patient communication leader to use funds to accelerate growth strategy

LONDON, UK - 29 September, 2011 - Leading growth equity and venture capital group Scottish Equity Partners (SEP) has led an initial £3m pound investment in Exco InTouch, the leading provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.

SEP has taken a minority stake in the company which will use the funds to accelerate its expansion, enabling it to take advantage of significant growth opportunities in the clinical technology sector, particularly in the emerging mobile patient communication market.

Manchester-based Analytical Technology Achieves Record Turnover as Water Industry Thrives

Manchester, UK (July 28, 2011) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that the company has gone from strength to strength since its inception in 1998, culminating in a record month for the business in June 2011. This spectacular achievement demonstrates the buoyancy of the current market for water monitoring instrumentation, despite the present economic recession. It is also a demonstration of the ongoing and imperative need for reliable water monitoring in the water utility industry to ensure a safe and continuous supply of water.


This year Manchester-based Analytical Technology has had its strongest first half ever and this culminated in June sales being the highest on record. A large component of the June sales, which peaked at £1.2 million for the month, can be credited to the recent contract signed by Analytical Technology with Severn Trent Water, involving the purchase of 250 Analytical Technology residual chlorine monitors in June alone. Analytical Technology is also supplying Yorkshire Water with more than 450 chlorine monitors and has enjoyed repeated success in recent years, providing instrumentation to other major utility companies such as United Utilities, Scottish Water, Thames Water, Anglian Water and South West Water.

Novozymes Biopharma secures business innovation award

Company recognized for its commitment to pushing back scientific frontiers and developing solutions that enhance the manufacture of medical devices and pharmaceuticals

NOTTINGHAM, UK – July 21, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, received the 2011 Nottingham Evening Post
(NEP) Business Award in the business innovation category, for its innovative recombinant human albumin range. The company has been recognized for its outstanding contribution to pushing back scientific frontiers by developing innovative, process improving solutions for the medical device and pharmaceutical manufacturing industries. The NEP business awards are designed to reward organizations in the region for setting new benchmarks in their industries and the company is delighted to add this accolade to its growing collection of awards.